US47103J1051
US47103J1051
Janux Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.12B EUR | 938.16M EUR | 846.03M EUR | 833.3M EUR |
Enterprise Value | 181.11M EUR | 931.38M EUR | 815.77M EUR | 803.11M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -7.01x | -- | -- | -- |
Price to Sales | 46.85x | 39.09x | 61.61x | 83.33x |
Price to Book | 1.21x | 1.01x | 0.9x | 0.87x |
EV/Revenue | 7.55x | 38.81x | 59.4x | 80.31x |
EV/EBITDA | -1.28x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -1.46% | -4.47% | -9.28% | -7.91% |